HMG20B anticorps

N° du produit ABIN272257

Détail du produit anti-HMG20B anticorps

Antigène: HMG20B (High Mobility Group 20B (HMG20B))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp HMG20B est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Specificité: This antibody detects endogenous levels of BRAF35 protein. (region surrounding Thr29)

Réactivité croisée (Details): Species reactivity (tested):Human.

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen

Pureté: > 95 % pure by SDS-PAGE

Information d'application

Indications d'application: ELISA: 1: 20000approx. 1: 40000. WB: 1: 500approx. 1: 1000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1,0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.2., 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: DO NOT FREEZE!

Stock: 4 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C.

Détails sur HMG20B

Antigène: HMG20B (High Mobility Group 20B (HMG20B))

Autre désignation: SMARCE1-Related Protein (HMG20B Produits)

Synonymes: anticorps BRAF25, anticorps BRAF35, anticorps HMGX2, anticorps HMGXB2, anticorps PP7706, anticorps SMARCE1r, anticorps SOXL, anticorps pp8857, anticorps AW610687, anticorps Hmgx2, anticorps Hmgxb2, anticorps Smarce1r, anticorps high mobility group 20 B, anticorps high mobility group 20B, anticorps Hmg20b, anticorps HMG20B

Sujet: The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45 % of families with high incidence of breast cancer and at least 80 % of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a 20 kDa complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesinlike coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.Synonyms: BRAF35, BRCA2-associated factor 35, HMG box-containing protein 20B, HMG domain-containing protein 2, HMG domain-containing protein HMGX2, HMG20B, HMGX2, HMGXB2, SMARCE1R, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related, Sox-like transcriptional factor, Structural DNA-binding protein BRAF35

Poids moléculaire: approx. 36 kDa

ID gène: 10362

NCBI Accession: NP_006330

UniProt: Q9P0W2